GSK's Blenrep Combo Gets Japan Review Nod
Ticker: GLAXF · Form: 6-K · Filed: Sep 17, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Sep 17, 2024 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 7 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, drug-review, japan
TL;DR
GSK's Blenrep combo for multiple myeloma is under review in Japan. Big market potential.
AI Summary
GSK plc announced on September 17, 2024, that its Blenrep (belantamab mafodotin) combinations for relapsed/refractory multiple myeloma have been accepted for regulatory review in Japan. This submission is supported by Phase III trial data.
Why It Matters
This regulatory acceptance in Japan could pave the way for expanded market access for Blenrep, potentially increasing revenue for GSK.
Risk Assessment
Risk Level: low — This is a routine regulatory filing announcing a submission for review, not a material event with immediate financial implications.
Key Players & Entities
- GSK plc (company) — Registrant
- Blenrep (drug) — Product under review
- belantamab mafodotin (drug) — Active ingredient of Blenrep
- Japan (country) — Jurisdiction of regulatory review
- September 17, 2024 (date) — Date of issuance
FAQ
What is the specific indication for Blenrep that has been accepted for review in Japan?
The filing states that the Blenrep combinations are for relapsed/refractory multiple myeloma.
What data supports the regulatory submission in Japan?
The submission is supported by Phase III trial data.
What is the name of the company filing this report?
The company filing this report is GSK plc.
On what date was this report issued?
This report was issued on 17 September 2024.
What is the primary purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, announcing regulatory review acceptance in Japan.
Filing Stats: 1,840 words · 7 min read · ~6 pages · Grade level 14.2 · Accepted 2024-09-17 07:11:02
Filing Documents
- a4081e.htm (6-K) — 51KB
- 0001654954-24-011988.txt ( ) — 52KB
SIGNATURES
SIGNATURES     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: September 17, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc